Lisa Olson - 20 Jul 2021 Form 4 Insider Report for Magenta Therapeutics, Inc. (DNTH)

Role
Head of Research and Chief Scientific Officer
Signature
/s/ Cindy Driscoll, Attorney-in-Fact for Lisa Olson
Issuer symbol
DNTH
Transactions as of
20 Jul 2021
Net transactions value
$0
Form type
4
Filing time
22 Jul 2021, 16:36:07 UTC
Next filing
03 Aug 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGTA Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 20 Jul 2021 Common Stock 50,000 $8.90 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over four years, with 25% of this option vesting on July 20, 2022, and the remainder vesting in 36 equal monthly installments thereafter.

Remarks:

Head of Research and Chief Scientific Officer